Skip to content

Efficacy of S-flurbiprofen Plaster in Moderate to Severe Knee Osteoarthritis: A Randomized Controlled Trial

Efficacy of S-flurbiprofen Plaster in Moderate to Severe Knee Osteoarthritis: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20241110007
Enrollment
60
Registered
2024-11-10
Start date
2024-12-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee pain in patient with moderate to severe knee OA (Kallgren-Lawrence type III - IV) Knee pain, Moderate to severe knee osteoarthritis, Kallgren-Lawrence type III - IV

Interventions

- The patients will have S-flurbiprofen plaster (SFPP) containing 40 mg of SFP in a 10 x 14 cm tape-type patch to apply once daily to the affected area - Rescue drugs during the treatment period are a
Active Comparator Drug,Placebo Comparator Drug
S-flurbiprofen plaster,Placebo

Sponsors

Faculty of Medicine, Prince of Songkla University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 50 - 75 years 2. Able to understand and use Thai language for communication (reading, speaking, writing) 3. Kallgren-Lawrence Grade III or IV osteoarthritis in target knee 4. Able to walk 5. Understood the visual analog scales (VAS) and able to fill the Knee Injury and Osteoarthritis Outcome Score (KOOS)

Exclusion criteria

Exclusion criteria: 1. Had past surgery in target knee 2. Received treatment including corticosteroids or intra-articular injection to the target knee within 14 days 3. History of hypersensitivity or allergy to NSAIDs, aspirin-induced asthma 4. History of dermatitis requiring treatment by any patch formulation 5. Pregnant, potentially pregnant or lactating women 6. Had other comorbidities: Neuropsychiatric disorder, dementia, renal failure (CrCl < 30 mL/min/1.73 m2), severe hypertension, peptic ulcer, skin disease, liver disease, severe blood disease, cardiac disease, infectious disease using quinolone antibiotics (e.g. norfloxacin), patients using precaution drugs (e.g. warfarin, LMWH, TCA, SSRI, SNRI,, immunosuppressive drugs; cyclosporine, methotrexate, anti-retroviral drugs; tenofovir) 7. Chronic pain patients using more potent pain control drug e.g. opioid

Design outcomes

Primary

MeasureTime frame
Pain levels at 1 week, 2 weeks and 4 weeks (2 weeks free of treatment) after starting the therapy The changes in visual analog scale (VAS) scores (0-100 mm) for pain levels ,Knee function at 1 week, 2 weeks and 4 weeks (2 weeks free of treatment) after starting the therapy The changes in Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaires

Secondary

MeasureTime frame
Adverse effects at 1 week, 2 weeks and 4 weeks (2 weeks free of treatment) after starting the therapy The adverse events complaint recorded in each appointment

Countries

Thailand

Contacts

Public ContactVarah Yuenyongviwat

Prince of Songkla Univeristy

Varah.y@psu.ac.th074451601

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026